Does the Autolus (AUTL) Form 3 show any share purchases or sales by Elisabeth Leiderman?

The Form 3 does not report any purchases or sales of Autolus shares. It presents three “holding” entries for option awards, indicating existing derivative positions rather than new open-market buy or sell transactions in the company’s American Depositary Shares.

Autolus director reports option holdings

Autolus Therapeutics plc director Elisabeth Leiderman filed an initial Form 3 reporting her holdings of three option awards over American Depositary Shares.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Autolus Therapeutics plc director Elisabeth Leiderman filed an initial Form 3 reporting her holdings of three option awards over American Depositary Shares. Each option covers 80,000 underlying ADS, with exercise prices of $5.5000, $3.4800 and $2.3200, expiring between December 20, 2033 and June 26, 2035. One grant is fully vested and exercisable, while the others vest in equal monthly installments beginning January 20, 2024 and July 26, 2025.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Leiderman Elisabeth

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--

Holdings After Transaction: Share Option (right to buy) — 240,000 contracts (Direct)

Footnotes (3)

F1. This option vested or vests in 36 equal monthly installments commencing on January 20, 2024.
F2. Fully vested and exercisable.
F3. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Autolus (AUTL) Form 3 filing by Elisabeth Leiderman show?

The Form 3 shows Elisabeth Leiderman’s existing option holdings in Autolus ADS. She reports three option awards, each linked to 80,000 American Depositary Shares, with exercise prices between $2.3200 and $5.5000 and expirations from 2033 to 2035.

How many Autolus (AUTL) shares are covered by Elisabeth Leiderman’s options?

Leiderman’s options each relate to 80,000 underlying Autolus ADS. The filing lists three separate “Share Option (right to buy)” positions, each tied to 80,000 American Depositary Shares, giving clear visibility into the scale of her potential equity exposure through these awards.

What are the exercise prices of Elisabeth Leiderman’s options in Autolus (AUTL)?

The reported options have exercise prices of $5.5000, $3.4800 and $2.3200 per ADS. These prices define the cost at which she may purchase Autolus American Depositary Shares if she chooses to exercise the options before expiration.

When do Elisabeth Leiderman’s Autolus (AUTL) options vest?

One option grant is fully vested, while two vest monthly over time. Footnotes state one award is fully vested, another vests in 36 equal monthly installments starting January 20, 2024, and a third in twelve equal monthly installments beginning July 26, 2025.

What are the expiration dates of the Autolus (AUTL) options held by Elisabeth Leiderman?

The options expire between December 20, 2033 and June 26, 2035. Specifically, the filing lists expiration dates of 2033-12-20, 2034-06-28 and 2035-06-26, defining the final dates by which each option must be exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 08:00 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Leiderman Elisabeth

(Last)

(First)

(Middle)

C/O AUTOLUS THERAPEUTICS PLC

THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

(Street)

LONDON

W12 7FP

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share Option (right to buy)	⁽¹⁾	12/20/2033	American Depositary Shares	80,000	$5.5	D
Share Option (right to buy)	⁽²⁾	06/28/2034	American Depositary Shares	80,000	$3.48	D
Share Option (right to buy)	⁽³⁾	06/26/2035	American Depositary Shares	80,000	$2.32	D

Explanation of Responses:

1. This option vested or vests in 36 equal monthly installments commencing on January 20, 2024.

2. Fully vested and exercisable.

3. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.

	/s/ Elisabeth Leiderman	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR